New liver drug candidate AD-230 enters first human tests
NCT ID NCT07521241
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial will test a new drug called AD-230 in 52 healthy adults to see how the body processes it and whether it is safe. The study uses a crossover design where each participant receives both AD-230 and a related version. Results will help decide if AD-230 should move into larger studies for chronic liver disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AD-230
What this could lead to
If successful, this trial will provide essential safety and dosing data to guide future studies of AD-230 for chronic liver disease.
What could go wrong
This is a very early Phase 1 study in healthy volunteers, not patients. It only measures drug levels and short-term safety, not whether the drug actually treats liver disease. Many drugs fail in later stages.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LIVER DISEASE (CLD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Kyungpook National university hospital
Seoul, South Korea
Contact Phone: •••-•••-•••• Email: •••••@•••••